ACTU Latest News

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

accessnewswire.com — Mar 24, 2026

Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a

Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey

defenseworld.net — Mar 10, 2026

Actuate Therapeutics (NASDAQ: ACTU - Get Free Report) and Gossamer Bio (NASDAQ: GOSS - Get Free Report) are both small-cap medical companies, but whic

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

globenewswire.com — Mar 9, 2026

CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

globenewswire.com — Feb 24, 2026

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc.

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

globenewswire.com — Jan 21, 2026

-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in spe